KRAS and melanoma: Recently, RASA2 and NRAS mutations were confirmed to be mutually exclusive, with NF1 mutations significantly co-occurring with RASA2 mutations in BRAF and NRAS wild-type melanomas, since RASA2 inhibits NRAS and NF1 inhibits KRAS and HRAS (Arafeh et al., 2019).